Skip to search formSkip to main contentSkip to account menu

Grade 2/3

A morphologic qualifier indicating that a neoplastic lesion is moderately to poorly differentiated.
National Institutes of Health

Related topics

Related topics

1 relation
Cervical Intraepithelial Neoplasia Grade 2/3

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Prognostic impact of prepercutaneous coronary intervention TIMI flow in patients with ST-segment and non-ST-segment elevation myocardial infarction: Results from the FAST-MI 2010 registry.
Review
2014
Review
2014
Long-Term Effects of Ruxolitinib on Bone Marrow Morphology in Patients With Myelofibrosis and Comparison to Best Available Therapy
2013
2013
Histologically unstable asymptomatic carotid plaques have altered expression of genes involved in chemokine signalling leading to localised plaque inflammation and rupture.
2011
2011
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy…
2006
2006
Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C.
2006
2006
Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3.
OBJECTIVE This study was undertaken to study the tolerability and efficacy of 5% imiquimod cream in the primary treatment of… 
2001
2001
A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report.
2000
2000
Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study.
1993
1993
Efficacy of subcutaneous sumatriptan in the acute treatment of early‐morning migraine: a placebo‐controlled trial
Abstract. Objectives. To evaluate the efficacy of self‐administered subcutaneous sumatriptan in the acute treatment of early… 
1987
1987
A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)